ASBP
Aspire Biopharma·NASDAQ
--
--(--)
--
--(--)
ASBP fundamentals
During Q3 2025, Aspire Biopharma (ASBP) reported revenue of 1.94K, a YoY change of 0.00%. Net income was -1.85M, a YoY change of -755.64%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Feb 9, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.94K -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 1.94K -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.06K -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 1.06K -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 884 -- | -- -- |
Operating Expenses | 7.73K -- | 2.38K -- | 15.31K -- | 755 -- | 109.22K +1313.47% | 297.84K +12398.53% | 255.26K +1567.26% | 314.03K +41493.38% | 324.56K +197.17% | 288.25K -3.22% | 324.74K +27.22% | 402.61K +28.21% | 230.97K -28.84% | 96.92K -66.37% | 215.26K -33.71% | 2.55M +532.25% | 15.56M +6635.28% | 799.89K +725.28% | 1.15M +432.57% | 20.05M -- |
Selling, General and Administrative Expenses | 7.73K -- | 2.38K -- | 15.31K -- | 755 -- | 109.22K +1313.47% | 297.84K +12398.53% | 255.26K +1567.26% | 314.03K +41493.38% | 324.56K +197.17% | 288.25K -3.22% | 324.74K +27.22% | 402.61K +28.21% | 220.47K -32.07% | 86.42K -70.02% | 208.26K -35.87% | 2.57M +539.20% | 15.29M +6836.72% | 447.00K +417.23% | 938.48K +350.64% | 19.25M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 87.67K -- | 0 -- | 16.68K -- | -104.34K -- | 219.84K +150.77% | 51.31K -- | 425.49K +2451.20% | 592.29K -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 25.48K -- | -- -- | -- -- | -- -- | 976.35K +3732.56% | -- -- | -- -- | 324.74K -- | 402.61K -58.76% | 132.80K -- | 86.42K -- | 191.58K -41.01% | 2.68M +565.12% | 15.07M +11250.22% | 395.69K +357.85% | 512.99K +167.77% | 18.66M -- |
Research and Development Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 10.50K -- | 10.50K -- | 7.00K -- | -28.00K -- | 263.09K +2405.65% | 352.89K +3260.83% | 207.90K +2869.99% | 795.88K -- |
Operating Income | -7.73K -- | -2.38K -- | -15.31K -- | -755 -- | -109.22K -1313.47% | -297.84K -12398.53% | -255.26K -1567.26% | -314.03K -41493.38% | -324.56K -197.17% | -288.25K +3.22% | -324.74K -27.22% | -402.61K -28.21% | -230.97K +28.84% | -96.92K +66.37% | -215.26K +33.71% | -2.55M -532.25% | -15.56M -6635.28% | -799.89K -725.28% | -1.15M -432.16% | -20.05M -- |
Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 0 -- | 21.39K -- | 418.53K -- | 1.33M -- | 2.54M -- | 3.20M +14844.13% | 2.10M +401.77% | 255.48K -80.83% | 251.70K -90.11% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -9.45M -3853.96% | -384.85K -- | -1.18M -- | -705.00K -- | -11.72M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -9.11M -- | -94.92K -- | -289.40K -- | 775.06K -- | -8.72M -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -364.11K -- | 0 -- | -- -- |
Net Interest Expense | -- -- | -- -- | -- -- | 0 -- | -21.39K -- | -418.53K -- | -1.33M -- | -2.54M -- | -3.20M -14844.13% | -2.10M -401.77% | -255.48K +80.83% | -251.70K +90.11% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 342.95K +236.25% | 289.93K -- | 527.89K -- | 1.48M -- | 2.64M -- |
Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 8.97K -- | 0 -- | 0 -- | 0 -- | 891.62K +9844.50% | 289.93K -- | 527.89K -- | 1.48M -- | 3.19M -- |
Interest Income | -- -- | -- -- | -- -- | 0 -- | 21.39K -- | 418.53K -- | 1.33M -- | 2.54M -- | 3.20M +14844.13% | 2.10M +401.77% | 255.48K -80.83% | 260.67K -89.75% | -- -- | -- -- | -- -- | 548.68K +110.49% | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -7.73K -- | -2.38K -- | -15.31K -- | -755 -- | -87.83K -1036.61% | 120.69K +5164.75% | 1.08M +7136.03% | 2.23M +295484.64% | 2.87M +3370.60% | 1.81M +1401.18% | -69.26K -106.43% | -150.91K -106.77% | -230.97K -108.04% | -96.92K -105.35% | -215.26K -210.80% | -8.93M -5818.08% | -15.94M -6801.90% | -1.98M -1944.19% | -1.85M -759.67% | -28.70M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.01K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- |
Net Income | -7.73K -- | -2.38K -- | -15.31K -- | -755 -- | -87.83K -1036.61% | 120.69K +5164.75% | 1.08M +7136.03% | 2.23M +295484.64% | 2.87M +3370.60% | 1.81M +1401.18% | -69.26K -106.43% | -150.91K -106.77% | -230.97K -108.04% | -96.92K -105.35% | -216.27K -212.27% | -8.93M -5818.08% | -15.94M -6801.90% | -1.98M -1944.19% | -1.85M -755.64% | -28.70M -- |
Net Income Attributable to Owners of the Company | -7.73K -- | -2.38K -- | -15.31K -- | -755 -- | -87.83K -1036.61% | 120.69K +5164.75% | 1.08M +7136.03% | 2.23M +295484.64% | 2.87M +3370.60% | 1.81M +1401.18% | -69.26K -106.43% | -150.91K -106.77% | -230.97K -108.04% | -96.92K -105.35% | -216.27K -212.27% | -11.99M -7847.22% | -15.94M -6801.90% | -1.98M -1944.19% | -1.85M -755.64% | -31.77M -- |
Net Income Attributable to Common Stockholders | -7.73K -- | -2.38K -- | -15.31K -- | -755 -- | -87.83K -1036.61% | 120.69K +5164.75% | 1.08M +7136.03% | 2.23M +295484.64% | 2.87M +3370.60% | 1.81M +1401.18% | -69.26K -106.43% | -150.91K -106.77% | -230.97K -108.04% | -96.92K -105.35% | -216.27K -212.27% | -11.99M -7847.22% | -15.94M -6801.90% | -1.98M -1944.19% | -1.85M -755.64% | -31.77M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -25.48K -- | -- -- | -- -- | -- -- | 3.34M +13211.83% | -- -- | -- -- | -69.26K -- | -150.91K -104.52% | -230.97K -- | -96.92K -- | -- -- | -12.54M -8207.80% | -15.94M -6801.90% | -1.98M -1944.19% | -- -- | -- -- |
Basic EPS | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0.03 -- | 0.06 -- | 0.08 -- | 0.09 -- | -0.01 -133.33% | -0.01 -116.67% | -0.01 -112.50% | 0 -100.00% | -0.01 -- | -1.24 -12300.00% | -0.42 -4100.00% | -0.04 -- | -0.04 -300.00% | -1.74 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.01 -- | -- -- | -0.01 -- | 0 -- | -0.01 -- | -- -- | -0.42 -4100.00% | -0.04 -- | -0.04 -300.00% | -- -- |
Diluted EPS | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0.03 -- | -- -- | 0.08 -- | 0.09 -- | -0.01 -133.33% | -- -- | -0.01 -112.50% | 0 -100.00% | -0.01 -- | -- -- | -0.42 -4100.00% | -0.04 -- | -0.04 -300.00% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.01 -- | -- -- | -0.01 -- | 0 -- | -0.01 -- | -- -- | -0.42 -4100.00% | -0.04 -- | -0.04 -300.00% | -- -- |
You can ask Aime
What does Aspire Biopharma do and what are its main business segments?What is the revenue and EPS growth rate for Aspire Biopharma year over year?What were the key takeaways from Aspire Biopharma’s earnings call?What is Aspire Biopharma's gross profit margin?What is the market's earnings forecast for Aspire Biopharma next quarter?Did Aspire Biopharma beat or miss consensus estimates last quarter?What factors drove the changes in Aspire Biopharma's revenue and profit?What were the key takeaways from Aspire Biopharma's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
